Business
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a bu
About this update from Ascendis Pharma A/s
[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tA.9j4XDPXN.zyLsOvv6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"TransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call today at 4:30 pm ET","length":35,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":296,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.","length":217,"tagName":"p"},{"type":"text","content":"“With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,” said Jan Mikkelsen, President and CEO of Ascendis Pharma. “With strong execution and the power of our TransCon platform, we are positioned to generate approximately €500 million in operating cash flow in 2026 while aspiring to deliver at least €5 billion in global annual product revenue by 2030. At the same time, we are advancing a growing pipeline of highly differentiated programs to deliver durable, long-term growth.”","length":606,"tagName":"p"},{"type":"text","content":"Select 2025 Highlights & Anticipated 2026 Milestones","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TransCon PTH(palopegteriparatide, marketed as YORVIPATH)","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":...